Innate Pharma (IPHA) Stock Analysis

Innate Pharma (IPHA) is a publicly traded company in the HEALTHCARE sector. It trades at $1.82, carries a market capitalization of $167.15M. This page summarizes the public market data, fundamentals, and frequently asked questions for IPHA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.82
• Market Cap: $167.15M
• EPS: $-0.64
• 52-Week High: $2.63
• 52-Week Low: $1.17

Market Sentiment

Innate Pharma currently has a Neutral sentiment score of 0.02.

About Innate Pharma

Innate Pharma SA is a pioneering biotechnology firm headquartered in Marseille, France, specializing in the development of groundbreaking therapeutic antibodies for oncological applications. The company boasts a diverse pipeline of proprietary immune-oncology candidates designed to improve treatment outcomes for cancer patients worldwide. With its strong focus on monoclonal antibody and immune-mediated therapies, Innate Pharma is well-positioned to capitalize on the increasing global demand f...

GNG Research Analysis

GNG Research scores Innate Pharma (IPHA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IPHA.

Frequently Asked Questions

Does IPHA pay dividends?

Innate Pharma (IPHA) does not currently pay a regular dividend.

What is IPHA's market cap?

Innate Pharma (IPHA) has a market capitalization of $167.15M with a current stock price of $1.82.